`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`KVK-Tech, Inc.
`Petitioner
`
`V.
`
`Shire PLC
`
`Patent Owner
`
`Case IPR2017-00290
`
`U.S. Patent No. 8,846,100
`
`DECLARATION OF CHAD LANDMON IN SUPPORT OF MOTION
`
`FOR ADMISSION PRO HAC VICE
`
`KVK-TECH EXHIBIT 1041
`
`KVK-TECH EXHIBIT 1041
`
`
`
`1, Chad Landmon, declare as follows:
`
`1.
`
`I was admitted to the Connecticut Bar in 1999 and the District of
`
`Columbia Bar in 2009.
`
`I have been practicing law for over 18 years. For more
`
`than 16 years, my practice has focused primarily on patent litigation.
`
`2.
`
`Over the course of my career, I have been counsel in over 40 patent
`
`litigations.
`
`3.
`
`I am a member of good standing in the Bars of Connecticut and the
`
`District of Columbia and am admitted to practice before the US. District Courts
`
`for the District of Columbia, District of Connecticut, Eastern District of Michigan
`
`and Southern District of New York. I am also admitted to practice before the US.
`
`Court of Appeals for the District of Columbia Court, the Federal Circuit, the
`
`Fourth Circuit, and the Sixth Circuit.
`
`4.
`
`My Connecticut Bar membership number is 417340. My District of
`
`Columbia Bar membership is 990347.
`
`5.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`6.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`
`
`7.
`
`I have read and will comply with the Patent Office Trial Practice
`
`Guide and the Board’s Rules for Practice for Trials, as set forth in 37 C.F.R. Part
`
`42.
`
`8.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and
`
`disciplinary jurisdiction under 37 CPR. § 1 l.l9(a).
`
`9.
`
`I have currently applied to appear pro hac vice in the following related
`
`proceeding before the United States Patent and Trademark Office IPR2017-00293.
`
`I have not applied to appear pro hac vice before the United States Patent and
`
`Trademark Office in any other proceedings in the last three years.
`
`10.
`
`In addition to this matter, I have represented KVK-Tech, Inc. or its
`
`affiliates in multiple patent and patent-related cases, including Purdue Pharma
`
`L.P. et al. V. KVK-Tech Inc. et al., 16—CV-00025 (D. Del.) and Purdue Pharma
`
`
`L.P. et 211. V. KVK-Tech Inc. et a1., l7-cv-00450 (D. 1361.).
`
`l 1.
`
`I am intimately familiar with the subject matter of US. Patent No.
`
`8,846,100. I am also intimately familiar with amphetamine salt formulations, such
`
`as Adderall XR® as a result of my participation as counsel in litigation related to
`
`Adderall XR®, specifically, Shire LLC et al. V. Abhai LLC, l:15-cv~l3909 (D.
`
`Mass). In addition, I have represented a number of life sciences and
`
`
`
`pharmaceutical companies in patent litigation matters before federal district
`
`courts and appellate courts. The technology in these disputes includes
`
`pharmaceutical compounds, including those for the treatment of attention deficit
`
`hyperactivity disorder, and method-of-treatment claims.
`
`12.
`
`I hereby declare that all statements made herein of my own
`
`knowledge are true and that all statements made on information and belief are
`
`believed to be true; and further that these statements and the like are punishable by
`
`fine, imprisonment, or both under Section 1001 of Title 18 of the United States
`
`Code.
`
`Date: January 8,2018
`
`Respectfully submitted,
`
`W % M
`
`Chad A. Landmon
`
`Axinn, Veltrop & Harkrider LLP
`90 State House Square
`Hartford, CT 06103
`(860) 275-8100
`
`